{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:59:04Z","timestamp":1790801944980,"version":"4.1.0"},"reference-count":105,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Market Access &amp; Health Policy"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/20016689.2023.2216518","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T11:34:38Z","timestamp":1685100878000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States"],"prefix":"10.3390","volume":"11","author":[{"given":"Alexa C.","family":"Klimchak","sequence":"first","affiliation":[{"name":"Global HEOR, RWE &amp; Analytics, Sarepta Therapeutics, Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Sedita","sequence":"additional","affiliation":[{"name":"Global HEOR, RWE &amp; Analytics, Sarepta Therapeutics, Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[{"name":"Research &amp; Development, Sarepta Therapeutics, Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Mendell","sequence":"additional","affiliation":[{"name":"Center for Gene Therapy, The Research Institute at Nationwide Children\u2019s Hospital, Columbus, OH, USA"},{"name":"Department of Pediatrics and Neurology, The Ohio State University, Columbus, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California Davis School of Medicine, Davis, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Gooch","sequence":"additional","affiliation":[{"name":"Global HEOR, RWE &amp; Analytics, Sarepta Therapeutics, Inc, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Malone","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Utah, Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20586"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043515"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.127"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200548"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijns5030027"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1725469"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2018.01.001"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/21678707.2013.746939"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198906153202405"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.08.004"},{"key":"e_1_3_6_18_1","unstructured":"US Food and Drug Administration. AMONDYS 45 prescribing information. 2021. Available from: https:\/\/www.amondys45.com\/Amondys45casimersenPrescribingInformation.pdf"},{"key":"e_1_3_6_19_1","unstructured":"US Food and Drug Administration. VYONDYS 53 (golodirsen) prescribing information. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2019\/211970s000lbl.pdf"},{"key":"e_1_3_6_20_1","unstructured":"US Food and Drug Administration. VILTEPSO (viltolarsen) injection for intravenous use. Prescribing information. 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212154s000lbl.pdf"},{"key":"e_1_3_6_21_1","unstructured":"US Food and Drug Administration. EXONDYS 51 (eteplirsen) prescribing information. 2019. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211970s000lbl.pdf"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"e_1_3_6_24_1","volume-title":"Presented at the 27th International Hybrid Annual Congress of the World Muscle Society","author":"Iff J","year":"2022","unstructured":"Iff J, Done N, Tuttle E, et al. Survival in eteplirsen-treated vs Duchenne muscular dystrophy (DMD) natural history controls: an indirect treatment comparison using real-world data. Presented at the 27th International Hybrid Annual Congress of the World Muscle Society; 2022 October 11\u201315; Halifax, Nova Scotia, Canada."},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210665"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/343180a0"},{"key":"e_1_3_6_28_1","doi-asserted-by":"crossref","unstructured":"Mendell JR Sahenk Z Lehman K et al. Phase 1\/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update. Paper presented at: 17th International Congress on Neuromuscular Diseases. 2022 July 5-9; Brussels Belgium.","DOI":"10.1016\/j.nmd.2022.07.251"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1484"},{"key":"e_1_3_6_30_1","doi-asserted-by":"crossref","unstructured":"Mendell JR Sahenk Z Lehman K et al. Phase 1\/2a trial of SRP-9001 in patients with Duchenne muscular dystrophy: 3-year safety and functional outcomes. Paper presented at: World Muscle Society Virtual Congress. 2021 Sep 20-24.","DOI":"10.1212\/WNL.98.18_supplement.2568"},{"key":"e_1_3_6_31_1","volume-title":"Paper presented at: 2021 MDA Virtual Clinical & Scientific Conference","author":"Mendell JR","year":"2021","unstructured":"Mendell JR, Shieh PB, Sahenk Z, et al. A randomized, double-blind, placebo-controlled, gene-delivery clinical trial of rAavrh74.Mhck7.micro-dystrophin for Duchenne muscular dystrophy. Paper presented at: 2021 MDA Virtual Clinical & Scientific Conference; 2021 Mar 15\u201318."},{"key":"e_1_3_6_32_1","unstructured":"Sarepta Therapeutics. Community Bulletin: eMBARK study (SRP-9001-301) enrollment update. 2022. Available from: https:\/\/www.sarepta.com\/community-bulletin-embark-study-srp-9001-301-enrollment-update"},{"key":"e_1_3_6_33_1","unstructured":"Ingram D Rodino-Klapac LR SRP-9001: new clinical data and integrated analysis. 2022 Jul 6. Available from: https:\/\/investorrelations.sarepta.com\/static-files\/b58a68ba-d97a-4505-9929-a097a12006e8"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02182-3"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.04.903"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00942-2"},{"key":"e_1_3_6_37_1","unstructured":"Institute for Clinical and Economic Review. Adapted value assessment methods for high-impact \u201csingle and short-term therapies\u201d (SSTs). 2019 Nov 12. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SST_FinalAdaptations_111219.pdf"},{"key":"e_1_3_6_38_1","unstructured":"Henderson N ISPOR issue panel roundup: are our HTA methods fit for purpose for gene therapies? Available from: https:\/\/www.ohe.org\/news\/ispor-issue-panel-roundup-are-our-hta-methods-fit-purpose-gene-therapies"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.012"},{"key":"e_1_3_6_40_1","unstructured":"National Institute for Health and Care Excellence. Interim process and methods of the highly specialised technologies programme updated to reflect 2017 changes. 2017. Available from: https:\/\/www.nice.org.uk\/media\/default\/about\/what-we-do\/nice-guidance\/nice-highly-specialised-technologies-guidance\/hst-interim-methods-process-guide-may-17.pdf"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1071\/AH16194"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2200102"},{"key":"e_1_3_6_43_1","unstructured":"Institute for Clinical and Economic Review. Modifications to the ICER value assessment framework for treatments for ultra-rare diseases. 2020 Jan 31. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_URD_Framework_Adapt_013120.pdf"},{"key":"e_1_3_6_44_1","unstructured":"National Institute for Health and Care Excellence. Clarifying meanings of absolute and proportional shortfall with examples. 2013 Sep 17. Available from: https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/OHE-Note-on-proportional-versus-absolute-shortfall.pdf"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/1758-5899.12387"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2016.01.012"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2018.04.001"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00413-6"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738211047019"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221097"},{"key":"e_1_3_6_52_1","unstructured":"Institute for Clinical and Economic Review. Deflazacort eteplirsen and golodirsen for Duchenne muscular dystrophy: effectiveness and value. 2022 Apr 22. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/Corrected_ICER_DMD-Final-Report_042222.pdf"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0461-5"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.06.366"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.07.004"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30025-5"},{"issue":"2","key":"e_1_3_6_57_1","first-page":"121","article-title":"Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients","volume":"31","author":"Passamano L","year":"2012","unstructured":"Passamano L, Taglia A, Palladino A, et al. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31(2):121\u2013125.","journal-title":"Acta Myol"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2022.04.008"},{"issue":"12","key":"e_1_3_6_59_1","first-page":"1","article-title":"United States life tables, 2018","volume":"69","author":"Arias E","year":"2020","unstructured":"Arias E, Xu JQ. United States life tables, 2018. National Vital Stat Rep. 2020;69(12):1\u201344.","journal-title":"National Vital Stat Rep"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.255"},{"key":"e_1_3_6_61_1","unstructured":"Zaidman C Proud C McDonald C et al. One-year ENDEAVOR data (ambulatory \u22654-to <8-year-olds): phase 1b trial of delandistrogenemoxeparvovecin Duchenne muscular dystrophy (DMD). Paper presented at: 17th International Congress on Neuromuscular Diseases (ICNMD). 2022 July 5-9; Brussels Belgium."},{"key":"e_1_3_6_62_1","volume-title":"Presented at the 27th International Annual Congress on the World Muscle Society (WMS) 2022","author":"Mendell JR","year":"2022","unstructured":"Mendell JR, Shieh PB, Sahenk Z, et al. A Phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec in patients with DMD. Presented at the 27th International Annual Congress on the World Muscle Society (WMS) 2022. 2022 October 11-15. Halifax, Canada."},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25951"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-54"},{"key":"e_1_3_6_65_1","doi-asserted-by":"crossref","unstructured":"Audhya IF Szabo SM Bever A et al. Estimating health state utilities in Duchenne muscular dystrophy (DMD) using the EQ5D and Health Utilities Index (HUI). Paper presented at: World Muscle Society. 2022 Oct 11-15; Halifax Canada.","DOI":"10.1186\/s41687-023-00671-y"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02117-1"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073818773029"},{"key":"e_1_3_6_69_1","unstructured":"Institute for Clinical and Economic Review. Cost-effectiveness the QALY and the evLYG. 2023 Apr 7. Available from: https:\/\/icer.org\/our-approach\/methods-process\/cost-effectiveness-the-qaly-and-the-evlyg\/"},{"key":"e_1_3_6_70_1","unstructured":"Institute for Clinical and Economic Review. Betibeglogene autotemcel for beta thalassemia: effectiveness and value. Final evidence report. 2022 Jul 19. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/11\/ICER_Beta-Thalassemia_Final-Report_071922.pdf"},{"key":"e_1_3_6_71_1","unstructured":"Institute for Clinical and Economic Review. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma final report. 2021 Jul 9. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Multiple-Myeloma_Final-Report_Update_070921.pdf"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.02.009"},{"key":"e_1_3_6_73_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022 Jan 31. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.18378"},{"key":"e_1_3_6_75_1","unstructured":"Zorginstituut Nederland. Guideline for economic evaluations in healthcare. 2016 [cited 2022 Jul 14]. Available from: https:\/\/english.zorginstituutnederland.nl\/binaries\/zinl-eng\/documenten\/reports\/2016\/06\/16\/guideline-for-economic-evaluations-in-healthcare\/Guideline+for+economic+evaluations+in+healthcare.pdf"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-019-0196-1"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.1238"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.065"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2016.1541"},{"key":"e_1_3_6_80_1","unstructured":"Darras BT Urion DK Ghosh PS Dystrophinopathies. In: Adam MP Everman DB Mirzaa GM et al editors. Dystrophinopathies. Seattle (WA): University of Washington Seattle; 1993-2022. [Updated 2022 Jan 20;cited 2000 Jan 20]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1119\/"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1922028"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484"},{"key":"e_1_3_6_83_1","unstructured":"Harris E Breaking down pricing of cell & gene therapies. 2019 Jun 18. Available from: https:\/\/www.cellandgene.com\/doc\/breaking-down-pricing-of-cell-gene-therapies-0001#:~:text=Cost%20of%20goods%2Fmanufacturing%20alone to%20provide%20access%20to%20patients."},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300027"},{"key":"e_1_3_6_85_1","unstructured":"Institute for Clinical and Economic Review. 2020-2023 Value assessment framework. Accessed October 16 2022. Available from: https:\/\/34eyj51jerf417itp82ufdoe-wpengine.netdna-ssl.com\/wp-content\/uploads\/2020\/10\/ICER_2020_2023_VAF_102220.pdf"},{"key":"e_1_3_6_86_1","unstructured":"National Institute of Health and Care Excellence. The guidelines manual. Process and methods [PMG6]. 2012. Accessed October 16 2022. Available from: https:\/\/www.nice.org.uk\/process\/pmg6\/chapter\/assessing-cost-effectiveness"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0216-0"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-80"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.00343"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1377\/forefront.20230503.153705"},{"key":"e_1_3_6_91_1","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Process and methods [PMG36]. 2022 [cited 2022 Oct 17]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.003"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2530"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2013.815420"},{"key":"e_1_3_6_95_1","unstructured":"National Institute for Health and Care Excellence. Mifamurtide for the treatment of osteosarcoma. 2011 Oct 26. Available from: https:\/\/www.nice.org.uk\/guidance\/ta235\/resources\/mifamurtide-for-the-treatment-of-osteosarcoma-pdf-82600372273093"},{"key":"e_1_3_6_96_1","unstructured":"Institute for Clinical and Economic Review. Spinraza\u00ae and zolgensma\u00ae for spinal muscular atrophy: effectiveness and value. 2019 May 24. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_110220.pdf"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-016-0782-5"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000669"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0210-9"},{"issue":"6","key":"e_1_3_6_100_1","first-page":"633","article-title":"The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States","volume":"23","author":"Thayer S","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017 Jun;23(6):633\u2013641.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27429"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-022-00500-8"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27011"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1304-8"},{"key":"e_1_3_6_105_1","volume-title":"Paper presented at: 25th International Annual Congress of the World Muscle Society- Virtual","author":"Johnston KM","year":"2020","unstructured":"Johnston KM, Salhany RM, Ciafaloni E, et al. The natural history of Becker muscular dystrophy (BMD) - a systematic literature review. Paper presented at: 25th International Annual Congress of the World Muscle Society- Virtual; 2020 Sep 30-Oct 2."},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.12.007"}],"container-title":["Journal of Market Access &amp; Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20016689.2023.2216518","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T01:32:39Z","timestamp":1729474359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/search?q=10.1080\/20016689.2023.2216518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/20016689.2023.2216518"],"URL":"https:\/\/doi.org\/10.1080\/20016689.2023.2216518","relation":{},"ISSN":["2001-6689"],"issn-type":[{"value":"2001-6689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=zjma20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2216518"}}